Alkermes
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.About ALKS
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.
CEORichard F. Pops
CEORichard F. Pops
Employees1,800
Employees1,800
HeadquartersDublin, Dublin
HeadquartersDublin, Dublin
Founded2011
Founded2011
Employees1,800
Employees1,800
ALKS Key Statistics
Market cap4.61B
Market cap4.61B
Price-Earnings ratio13.86
Price-Earnings ratio13.86
Dividend yield—
Dividend yield—
Average volume1.56M
Average volume1.56M
High today$28.17
High today$28.17
Low today$27.68
Low today$27.68
Open price$27.95
Open price$27.95
Volume469.06K
Volume469.06K
52 Week high$36.45
52 Week high$36.45
52 Week low$25.17
52 Week low$25.17
Stock Snapshot
The current Alkermes(ALKS) stock price is $27.90, with a market capitalization of 4.61B. The stock trades at a price-to-earnings (P/E) ratio of 13.86.
On 2025-12-31, Alkermes(ALKS) stock traded between a low of $27.68 and a high of $28.17. Shares are currently priced at $27.90, which is +0.8% above the low and -1.0% below the high.
The Alkermes(ALKS)'s current trading volume is 469.06K, compared to an average daily volume of 1.56M.
In the last year, Alkermes(ALKS) shares hit a 52-week high of $36.45 and a 52-week low of $25.17.
In the last year, Alkermes(ALKS) shares hit a 52-week high of $36.45 and a 52-week low of $25.17.
Analyst ratings
81%
of 16 ratingsBuy
81.3%
Hold
18.8%
Sell
0%
People also own
Based on the portfolios of people who own ALKS. This list is generated using Robinhood data, and it’s not a recommendation.